BACE Inhibitors: Postmortem on One, Live Updates on Two
17 May 2019
At the AD/PD 2019 conference held recently in Lisbon, the amyloid hypothesis was reeling from repeated gut punches in the clinic. Both antibodies and BACE inhibitors are facing relentless criticism from academic scientists and biopharma analysts (e.g., May 2019 news). Lost in the cacophony can be the voices of patients and their families urging researchers to push on, and of site leaders who swear they “saw something” among their participants. A little lost as well, amid all the opinion, can be the data itself. Some anti-amyloid investigational antibodies (see Part 15 of this series) and the active vaccine CAD106 are still in Phase 3 or 2/3, as are elenbecestat and umibecestat. In Lisbon, scientists presented and debated data on both these extant BACE inhibitors as well as an extinct one, lanabecestat.
.png)
No hay comentarios:
Publicar un comentario